DOES BODY MASS INDEX IMPACT LONG-TERM RETENTION WITH ABATACEPT IN PATIENTS WITH RA WHO HAVE RECEIVED AT LEAST ONE PRIOR BIOLOGIC AGENT? 2-YEAR RESULTS FROM A REAL-WORLD, INTERNATIONAL, PROSPECTIVE STUDY

被引：0

作者：

Nuesslein, H. ^{[1
]}

Alten, R. ^{[2
]}

Galeazzi, M. ^{[3
]}

Lorenz, H. ^{[4
]}

Nurmohamed, M. ^{[5
]}

Benson, W. ^{[6
,7
]}

Burmester, G. ^{[8
]}

Peter, H. ^{[9
]}

Peichl, P. ^{[10
]}

Pavelka, P. ^{[11
]}

Chartier, M. ^{[12
]}

Poncet, C. ^{[13
]}

Rauch, C. ^{[14
]}

Le Bars, M. ^{[14
]}

机构：

[1] Internist Schwerpunktpraxis, Mannheim, Germany

[2] Schlosspark Klin Univ Med, Berlin, Germany

[3] Univ Siena, I-53100 Siena, Italy

[4] Univ Hosp, Heidelberg, Germany

[5] Vrije Univ Amsterdam, Med Ctr, Jan Van Breeman Res Inst, Amsterdam, Netherlands

[6] St Josephs Hosp, Guntur, Andhra Pradesh, India

[7] McMaster Univ, Hamilton, ON L8S 4L8, Canada

[8] Charite, Berlin, Germany

[9] Univ Freiburg, Freiburg, Germany

[10] Evangel Krankenhaus, Berlin, Germany

[11] Charles Univ Prague, Inst Rheumatol, CR-11636 Prague 1, Czech Republic

[12] Chiltern Int, London, England

[13] Docs Int, The Hague, Netherlands

[14] Bristol Myers Squibb, Lawrenceville, NJ USA

来源：

INTERNAL MEDICINE JOURNAL | 2015年 / 45卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ARP75

引用

页码：31 / 32

页数：2

共 30 条

[1] Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
Nuesslein, H.
Alten, R.
Galeazzi, M.
Lorenz, H. M.
Nurmohamed, M. T.
Bensen, W. G.
Burmester, Gerd
Peter, H-H
Peichl, P.
Pavelka, K.
Chartier, M.
Poncet, C.
Rauch, C.
Le Bars, M.
[J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1088 - S1089
[2] DOES BODY MASS INDEX IMPACT LONG-TERM RETENTION WITH ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE RECEIVED AT LEAST ONE PRIOR BIOLOGIC AGENT? 2-YEAR RESULTS FROM A REAL-WORLD, INTERNATIONAL, PROSPECTIVE STUDY
Nuesslein, Hubert
Alten, Rieke
Galeazzi, Mauro
Lorenz, Hanns-Martin
Nurmohamed, Michael T.
Bensen, William G.
Burmester, Gerd R.
Peter, Hans-Hartmut
Peichl, Peter
Pavelka, Karel
Chartier, Melanie
Poncet, Coralie
Rauch, Christiane
Le Bars, Manuela
[J]. RHEUMATOLOGY, 2015, 54 : 186 - 187
[3] Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
Nuesslein, H.
Alten, R.
Galeazzi, M.
Lorenz, H. M.
Nurmohamed, M. T.
Bensen, W. G.
Burmester, Gerd
Peter, H-H
Peichl, P.
Pavelka, K.
Chartier, M.
Poncet, C.
Rauch, C.
Le Bars, M.
[J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1087 - S1088
[4] PROGNOSTIC FACTORS FOR INTRAVENOUS ABATACEPT RETENTION IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR BIOLOGIC AGENT: 2-YEAR RESULTS FROM A PROSPECTIVE, INTERNATIONAL, REAL-WORLD STUDY
Nuesslein, Hubert
Alten, Rieke
Galeazzi, Mauro
Lorenz, Hanns-Martin
Nurmohamed, Michael T.
Bensen, William G.
Burmester, Gerd R.
Peter, Hans-Hartmut
Peichl, Peter
Pavelka, Karel
Chartier, Melanie
Poncet, Coralie
Rauch, Christiane
Le Bars, Manuela
[J]. RHEUMATOLOGY, 2015, 54 : 77 - 78
[5] Body Mass Index Does Not Influence the Efficacy of Abatacept in Patients with RA Who Are Biologic Naive: 6-Month Results from a Real-World, International, Prospective Study
Alten, R.
Nuesslein, H. G.
Galeazzi, M.
Lorenz, H-M
Mariette, X.
Cantagrel, A.
Chartier, M.
Desachy, G.
Poncet, C.
Rauch, C.
Le Bars, M.
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[6] PREDICTORS OF RETENTION WITH ABATACEPT IN PATIENTS WHO HAVE FAILED ONE OR MORE BIOLOGIC AGENTS: RESULTS FROM THE INTERNATIONAL, REAL-WORLD ACTION STUDY
Nuesslein, Hubert
Alten, Rieke
Galeazzi, Maurizio
Lorenz, Hannes M.
Nurmohamed, Michael T.
Bensen, William
Burmester, Gerd R.
Peter, Hans-Hartmut
Pavelka, Karel
Chartier, Melanie
Poncet, Coralie
Rauch, Christiane
Le Bars, Manuela
[J]. RHEUMATOLOGY, 2014, 53 : 94 - 95
[7] Predictors of retention with abatacept in patients who have failed one or more biologic agents: results from the international, real-world ACTION study
Nuesslein, H.
Alten, R.
Galeazzi, M.
Lorenz, H.
Boumpas, D.
Nurmohamed, M.
Bensen, W.
Burmester, G.
Peter, H.
Rainer, F.
Pavelka, K.
Chartier, M.
Poncet, C.
Rauch, C.
LeBars, M.
[J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 108 - 108
[8] PREDICTORS OF RETENTION WITH ABATACEPT IN PATIENTS WHO HAVE FAILED ONE OR MORE BIOLOGIC AGENTS: RESULTS FROM THE INTERNATIONAL, REAL-WORLD ACTION STUDY
Nuesslein, H.
Alten, R.
Galeazzi, M.
Lorenz, H. M.
Boumpas, D.
Nurmohamed, M. T.
Bensen, W. G.
Burmester, G. R.
Peter, H. -H.
Rainer, F.
Pavelka, K.
Chartier, M.
Poncet, C.
Rauch, C.
Le Bars, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 616 - 616
[9] Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
Nuesslein, Hubert G.
Alten, Rieke
Galeazzi, Mauro
Lorenz, Hanns-Martin
Nurmohamed, Michael T.
Bensen, William G.
Burmester, Gerd R.
Peter, Hans-Hartmut
Pavelka, Karel
Chartier, Melanie
Poncet, Coralie
Rauch, Christiane
Le Bars, Manuela
[J]. BMC MUSCULOSKELETAL DISORDERS, 2015, 16
[10] Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
Hubert G. Nüßlein
Rieke Alten
Mauro Galeazzi
Hanns-Martin Lorenz
Michael T. Nurmohamed
William G. Bensen
Gerd R. Burmester
Hans-Hartmut Peter
Karel Pavelka
Melanie Chartier
Coralie Poncet
Christiane Rauch
Manuela Le Bars
[J]. BMC Musculoskeletal Disorders, 16

← 1 2 3 →